Why Erasca, Inc.’s (ERAS) Stock Is Down 6.00%
As of Monday, October 05, Erasca, Inc.’s ERAS share price has dipped by 6.00%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Commentary & Analysis
Why Erasca, Inc.’s (ERAS) Stock Is Up 5.07%
As of Wednesday, September 30, Erasca, Inc.’s ERAS share price has surged by 5.07%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Erasca, Inc.’s (ERAS) Stock Is Down 6.82%
As of Wednesday, September 23, Erasca, Inc.’s ERAS share price has dipped by 6.82%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Erasca, Inc.’s (ERAS) Stock Is Up 7.72%
As of Thursday, September 10, Erasca, Inc.’s ERAS share price has surged by 7.72%, which has investors questioning if this is right time to sell.Michael Rose
Why Erasca, Inc.’s (ERAS) Stock Is Down 5.37%
As of Wednesday, September 02, Erasca, Inc.’s ERAS share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5,407.3 | $237.5 | 69% |
|
| Shares Out (Mil) | 311.3 | 53.9 | 83% |
|
| Institutional Ownership | 86.9% | 93.1% | 55% |
|
| Float (Mil) | 255.2 | 41.4 | 77% |
|
| Beta | 0.64 | 0.95 | 37% |
|
| Avg Daily Volume (000s) | 5,507 | 628 | 93% |
|
| Price Change (52-week) |
531.0% | 49.0% | 100% |
|
| Growth | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.4% | na |
|
| Net Income (5yr) | (4.1%) | (10.2%) | 35% |
|
| EPS (5yr) | 38.1% | 15.7% | 88 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (59.0%) | (15.7%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.130) | ($0.976) | ($0.623) | |
| Month Ago EPS | ($0.130) | ($0.976) | ($0.623) | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.121) | ($0.959) | ($0.556) | |
| Year/Year Chg | (8.5%) | 122.3% | 78.4% | |
| Financials | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($287) | ($44) | 5% |
|
| EPS (TTM) | ($0.971) | ($1.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($98) | ($33) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($24) | $2 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $39 | $4 | 37% |
|
| Enterprise Value (Q1) (Mil) | $4,921 | $174 | 63% |
|
| Valuation | ERAS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.33 | 2.27 | 93% |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (65.2%) | (47.7%) | 9% |
|
| ROE | (78.2%) | (55.0%) | 11% |
|
| Liabilities to Assets | 16.8% | 29.4% | 11% |
|
| F-Score | 1 | 2 | 1% |
|
Erasca, Inc. did not pass any screens on 10/12/2026.
